ISTH 2022 Congress Archives - ISTH Congress Abstracts

Abstract Number: LB 01.1

A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

G. Kenet¹, B. Nolan², B. Zulfikar³, B. Antmen⁴, P. Kampmann⁵, T. Matsushita⁶, C. You⁷, K. Vilchevska⁸, C. Bagot⁹, A. Sharif¹⁰, F. Peyvandi¹¹, G. Young¹², C. Negrier¹³, T. Quan¹⁴, S. Poloskey¹⁵, C. Sussebach¹⁶, F. Shammas¹⁷, S. Andersson¹⁸, B. Mei¹⁸, K. Kavakli¹⁹
Abstract Number: LB 01.2

Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial

V. Jiménez Yuste¹, P. Angchaisuksiri², G. Castaman³, K. Cepo⁴, J. Haaning⁴, S. Jacobsen⁴, J. Mahlangu⁵, T. Matsushita⁶, K. Nogami⁷, A. Shapiro⁸
Abstract Number: LB 01.3

Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

J. Mahlangu¹, H. Chambost², S. Chou³, A. Dunn⁴, A. von Drygalski⁵, R. Kaczmarek⁶, G. Kenet⁷, M. Laffan⁸, A. Leavitt⁹, B. Madan¹⁰, J. Mason¹¹, J. Oldenburg¹², M. Ozelo¹³, F. Peyvandi¹⁴, D. Quon¹⁵, M. Reding¹⁶, S. Shapiro¹⁷, H. Yu¹⁸, T. Robinson¹⁸, S. Pipe¹⁹
Abstract Number: LB 01.4

Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

A. von Drygalski¹, P. Chowdary², R. Kulkarni³, S. Susen⁴, B. Konkle⁵, J. Oldenburg⁶, D. Matino⁷, R. Klamroth⁸, A. Weyand⁹, V. Jimenez Yuste¹⁰, K. Nogami¹¹, S. Poloskey¹², B. Winding¹³, A. Willemze¹⁴, K. Knobe¹⁵
Abstract Number: LB 01.5

Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis

H. Vu¹, T. Kohs¹, J. Pang¹, K. Jordan¹, T. Zheng¹, P. Kievit², J. Johnson¹, M. Wallisch³, M. Hinds¹, C. Puy¹, C. Lorentz³, E. Tucker⁴, D. Gailani⁵, J. Aslan¹, J. Shatzel¹, O. McCarty⁶, I. Parra-Izquierdo¹
Abstract Number: LB 02.1

Intermediate versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow Study)

I. Bistervels¹, A. Buchmuller², H. Wiegers³, F. Ní Áinle⁴, B. Tardy⁵, J. Donnelly⁶, P. Verhamme⁷, A. Jacobsen⁸, A. Hansen⁹, M. Rodger¹⁰, M. DeSancho¹¹, R. Shmakov¹², N. van Es³, M. Prins¹³, C. Chauleur¹⁴, S. Middeldorp¹⁵
Abstract Number: LB 02.2

Hemorrhagic, Coagulopathic, and Thrombotic (HECTOR) Complications Among Critically-Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study

J. Fanning¹, R. Fanning², N. Weaver³, M. Griffee⁴, S. Cho¹, M. Panigada⁵, A. Zaaqoq⁶, N. White⁷, N. Obonyo⁸, A. Labib⁹, Y. Chia¹⁰, B. Fan¹¹, R. Arora¹², D. Chiumello¹³, A. Torres¹⁴, J. Suen¹⁵, G. Li Bassi¹⁵, G. Peek¹⁶, J. Fraser¹⁵, H. Dalton¹⁷
Abstract Number: LB 02.3

Sirtuin 1 as an endogenous inhibitor of NETosis

L. Wang¹, C. Yuen¹, S. Wong²
Abstract Number: LB 02.4

Platelets as Versatile Effectors of Thromboinflammation in Chronic Myeloproliferative Neoplasms

A. Krishnan¹, Z. Shen²
Abstract Number: LB 02.5

Roles of FVIII in endothelial cell biology more than a coagulation factor

c. olgasi¹, A. Cucci², S. Assanelli², C. Sgromo², C. Borsotti², G. Walker², I. Molineris³, F. Anselmi³, S. Oliviero³, A. Follenzi⁴
Abstract Number: OC 01.1

Base and Prime editing of DNA as a new therapeutic option for Hemophilia A

E. Tonetto¹, S. Pignani², G. Roman², A. Follenzi², F. Bernardi³, D. Liu⁴, M. Pinotti¹, D. Balestra¹
Abstract Number: OC 01.2

Improvements in Health-Related Quality of Life in Adults with Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy

R. Itzler¹, J. Miller², R. Robson², P. Monahan³, S. Pipe⁴
Abstract Number: OC 01.3

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

A. Sternberg, B. Samelson-Jones, L. George
Abstract Number: OC 01.5

Innate and Adaptive Immune Responses to Adeno-Associated Viral Gene Therapy in the Severe Hemophilia A Dog Model

P. Batty¹, A. Mo², M. Ashrafali³, B. Yates³, A. Gonzalez³, B. Handyside³, L. Harpell², D. Hurlbut², A. Menard⁴, A. Pender², L. Razon³, C. Sihn³, A. Winterborn², S. Fong³, D. Lillicrap⁵
Abstract Number: OC 02.1

Complement Receptors Mediate Binding of Heparin-Induced Thrombocytopenia Immune Complexes to Fc Receptor Bearing Cells

H. Harris¹, S. Khandelwal², L. Rauova³, D. Cines⁴, G. Arepally²
Abstract Number: OC 02.2

Cooperation between PF4-specific antibodies in heparin-induced thrombocytopenia: a new mechanism potentially contributing to hypercoagulability and thrombosis

S. Billy¹, C. Vayne², N. Charuel³, L. Coënon³, M. Atsouawe³, C. Pouplard⁴, Y. Gruel², J. Rollin²
Abstract Number: OC 02.3

“Off-the-shelf” cryopreserved platelets for the detection of HIT and VITT antibodies

A. Kanack¹, C. Jones², N. Splinter³, R. Leger³, N. Heikal³, D. Chen³, R. Pruthi³, G. George⁴, Y. Abou-Ismail⁵, G. Wool⁶, K. Gundabolu⁷, A. Padmanabhan³
Abstract Number: OC 02.4

Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies

A. Padmanabhan¹, A. Kanack², B. Singh¹, G. George³, K. Gundabolu⁴, S. Koepsell⁴, Y. Abou-Ismail⁵, K. Moser⁵, K. Smock⁵, D. Green⁶, A. Major⁷, C. Chan⁷, G. Wool⁷, M. Reding⁸, A. Ashrani¹, A. Bayas⁹, D. Grill¹
Abstract Number: OC 02.5

In vivo murine studies demonstrate that neutrophil activation by anti-NAP2 antibodies contributes to vaccine-induced immune thrombocytopenia and thrombosis (VITT)

C. Field¹, H. Kim², M. Kowalska², M. Weitzman², G. Arepally³, D. Cines⁴, L. Rauova², M. Poncz²
Abstract Number: OC 03.1

Factor XII heavy chain structure

J. EMSLEY¹, M. saleem², C. Li¹, H. Philippou³